Imiquad

Imiquad

imiquimod

Manufacturer:

Glenmark

Distributor:

Glenmark
Concise Prescribing Info
Contents
Imiquimod
Indications/Uses
Clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults; biopsy-confirmed, primary superficial basal cell carcinoma (sBCC) in immunocompetent adults. External genital & perianal warts/condyloma acuminata in patients >12 yr.
Dosage/Direction for Use
Actinic keratosis Apply 2 times/wk for full 16 wk to a defined treatment area. Superficial basal cell carcinoma 5 times/wk for a full 6 wk to the affected area. External genital warts 3 times/wk to affected area, continue until there is total clearance of the genital/perianal warts or max of 16 wk.
Special Precautions
May exacerbate inflammatory conditions of the skin, including chronic graft versus host disease. Discontinue for severe vulvar swelling. Consider interruption of dosing if systemic reactions occur. Minimize or avoid natural or artificial sunlight exposure. Actinic keratosis; other types of basal cell carcinoma including nodular & morpheaform (fibrosing or sclerosing) types; superficial basal cell carcinoma lesions on the face, head & anogenital area. Pregnancy & lactation. Childn.
Adverse Reactions
Application site disorders, remote site reactions, fatigue, fever, flu-like symptoms, headache, diarrhea, myalgia.
MIMS Class
Warts & Calluses Preparations
ATC Classification
D06BB10 - imiquimod ; Belongs to the class of topical antivirals used in the treatment of dermatological diseases.
Presentation/Packing
Form
Imiquad cream 5%
Packing/Price
250 mg x 3 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in